procentare

[Jack Prescott @JackPrescottX]

$ABCL insider buying from CEO Carl Hansen today @ $3.27

[procentare @Procentare]

@Investpold22 I don’t think that is the case. I am bullish, but the only way up from here that I see it is news about partner advancements or clinical trial updates. Another red market day and we will tank more. But I hope I am wrong :)

[procentare @Procentare]

@Aktieprenoren Du är en av få som postar en ”riktig” årssammanfattning, det har du i alla fall min respekt för, snyggt 2025 👏!

[procentare @Procentare]

@JackPrescottX @AbCelleraBio Time will tell if our patience will pay off, but this talk is legendary and he is a big reason as to why I own this stock. So much wisdom and has a view on business that I really like.

[procentare @Procentare]

@Djurvaenn Har han vunnit en mattetävling i Kina?

[procentare @Procentare]

@Algo_Stoney squeeeeeeeeeeeeze em

[procentare @Procentare]

@A_May_MD What am I seeing here? Are these post close market moves?

[Jack Prescott @JackPrescottX]

$ABCL Hits a 52 week high and scratches $7.62 after hours.

If you’re wondering what AbCellera does, this is the most succinct summary I’ve read.. comes from @DCVC, who invested when the company was still private.

“This approach creates an unprecedented "deep search" of the immune system. By going deep, AbCellera discovers antibodies that are completely invisible to hybridoma methods: potent neutralizing antibodies against difficult targets like GPCRs and ion channels; antibodies with specificity present in less than 1 in 100,000 B cells; and (overcoming tolerance) hundreds of antibodies against antigens that are 100% identical with the host. AbCellera analyzes the entire antibody repertoire to identify hundreds of drug candidates, and combines these sequences with data from automated assays testing antibody-epitope recognition, affinity, developability, and potency. This creates a powerful engine for the discovery and selection of high-quality antibody candidates for drugs.”

Basically, AbCellera doesn’t use AI to create antibodies from scratch, but rather leverages a natural immune response and uses AI to do a deep search through it with a human in the loop to select the ideal antibody candidate. Millions of antibodies screened. Single cell analysis. I believe this method of leveraging AI is powerful.

Understand >> Design

P.S: Why did the stock shoot up 40% today? I don’t know. All I know is that if the thesis plays out, this is still just the beginning.

Long and strong.

[procentare @Procentare]

@iHooghvorst @JackPrescottX Haha i have the same picture after watching the interviews with Carl, but always interesting to hear your perspective, thanks, what a day today, not surprised, but amazing to see!

[procentare @Procentare]

@unfixed_income @Aktieprenoren Middag - Solen

[procentare @Procentare]

@EkonomiGabriel Har du någon tråd där du samlat alla semlor du testat?

[procentare @Procentare]

@RLSInvest Kvar några $MAHA?

[procentare @Procentare]

@notequalzero Inte 1 april idag.

[procentare @Procentare]

@Aktieprenoren Den absolut bästa på twitter på att visa många sunda inställningar till börsen, både sett till att visa "man äger sina misstag" men också den transparens du visar och dina tankar du delar med dig av. Enormt imponerad och stort grattis till framgången i ditt bolag!

[procentare @Procentare]

@gunnarssonerik1 @Jayofcar Thanks, exciting stuff.

[procentare @Procentare]

@gunnarssonerik1 @Jayofcar <3 - thanks! If chatgpt could help me use the internet I would have found it!!!

[procentare @Procentare]

@Jayofcar @gunnarssonerik1 I have not found anything, but the agreement signed 2019 should indicate that this is most likely a antibody developed together with $ABCL as that was why they wanted to work together with $ABCL. Have not found anything to clarify it thou, yet.

[procentare @Procentare]

@Aktieprenoren @hofmannjesper Stort grattis!

[procentare @Procentare]

@Borspodden @RemindMe_OfThis 1 january 2023